Opportunity
Simpler Grants.gov #PAR-25-104
NIH Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
Buyer
National Institutes of Health
Posted
November 05, 2024
Respond By
October 25, 2027
Identifier
PAR-25-104
NAICS
541715
This opportunity from the National Institutes of Health (NIH) invites applications for the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional). - Government Buyer: - National Institutes of Health (NIH) is the sole government agency involved - Products/Services Requested: - Support for planning and preparatory studies to facilitate well-designed clinical trials in cancer prevention and control - Areas of focus include prevention/interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and long-term outcomes for cancer survivors - Activities may include feasibility assessments, protocol development, and testing of new trial designs to minimize infrastructure and reduce costs - OEMs and Vendors: - No specific Original Equipment Manufacturers (OEMs) or vendors are mentioned, as this is a research grant opportunity - Unique or Notable Requirements: - Open to a wide range of eligible organizations, including nonprofits, educational institutions, tribal governments, and small businesses - Emphasis on addressing information gaps that hinder clinical trial protocol finalization and feasibility - Encourages innovative approaches to trial design and cost reduction
Description
This funding opportunity aims to support well-planned clinical trials across the cancer prevention and control spectrum. The focus is on improving prevention, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and long-term outcomes of cancer survivors. The program addresses information gaps that can hinder trial protocol finalization and feasibility, thereby improving trial design and saving time and resources. Preparatory studies are encouraged to test new trial designs that minimize infrastructure and reduce costs.